Sustainable use of CRISPR/Cas in fish aquaculture: the biosafety perspective
Transgenic Research · 2022-02 · 31 (1) · 1-21
DOI: 10.1007/s11248-021-00274-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transgenic Research, online erschienen am 25.07.2021. Verfasst von Arinze S Okoli und 4 weiteren Autor:innen. Beteiligte Einrichtung: GenØk -Centre for Biosafety, SIVA Innovation Centre, Tromsø, Norway. aso023@uit.no. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Containment of Biohazards. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aquaculture is becoming the primary source of seafood for human diets, and farmed fish aquaculture is one of its fastest growing sectors. The industry currently faces several challenges including infectious and parasitic diseases, reduced viability, fertility reduction, slow growth, escapee fish and environmental pollution. The commercialization of the growth-enhanced AquAdvantage salmon and the CRISPR/Cas9-developed tilapia ( Oreochromis niloticus ) proffers genetic engineering and genome editing tools, e.g. CRISPR/Cas, as potential solutions to these challenges. Future traits being developed in different fish species include disease resistance, sterility, and enhanced growth. Despite these notable advances, off-target effect and non-clarification of trait-related genes among other technical challenges hinder full realization of CRISPR/Cas potentials in fish breeding. In addition, current regulatory and risk assessment frameworks are not fit-for purpose regarding the challenges of CRISPR/Cas notwithstanding that public and regulatory acceptance are key to commercialization of products of the new technology. In this study, we discuss how CRISPR/Cas can be used to overcome some of these limitations focusing on diseases and environmental release in farmed fish aquaculture. We further present technical limitations, regulatory and risk assessment challenges of the use of CRISPR/Cas, and proffer research strategies that will provide much-needed data for regulatory decisions, risk assessments, increased public awareness and sustainable applications of CRISPR/Cas in fish aquaculture with emphasis on Atlantic salmon ( Salmo salar ) breeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- GenØk -Centre for Biosafety, SIVA Innovation Centre, Tromsø, Norway. aso023@uit.no.
- GenØk -Centre for Biosafety, SIVA Innovation Centre, Tromsø, Norway.
- The Norwegian College of Fishery Science, The Arctic University of Norway (UiT), Tromsø, Norway.
- Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Qingdao, 266071, China.
- Qingdao Vland Biotech Company Group, Qingdao, 266061, China.
ORCID-Profile: Arinze S Okoli, Anne I Myhr
Zitieren
APA
Okoli, A. S., Blix, T., Myhr, A. I., Xu, W., & Xu, X. (2022). Sustainable use of CRISPR/Cas in fish aquaculture: the biosafety perspective. Transgenic Research, 31(1), 1-21. https://doi.org/10.1007/s11248-021-00274-7
Vancouver
Okoli AS, Blix T, Myhr AI, Xu W, Xu X. Sustainable use of CRISPR/Cas in fish aquaculture: the biosafety perspective. Transgenic Research. 2022;31(1):1-21. doi:10.1007/s11248-021-00274-7
BibTeX
@article{Okoli2022,
author = {Okoli, Arinze S and Blix, Torill and Myhr, Anne I and Xu, Wenteng and Xu, Xiaodong},
title = {Sustainable use of CRISPR/Cas in fish aquaculture: the biosafety perspective},
journal = {Transgenic Research},
year = {2022},
volume = {31},
number = {1},
pages = {1--21},
doi = {10.1007/s11248-021-00274-7}
}
EUVIMED